Qingdao Kingking Applied Chemistry Valuation

Is 002094 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002094 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 002094's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 002094's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002094?

Key metric: As 002094 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002094. This is calculated by dividing 002094's market cap by their current earnings.
What is 002094's PE Ratio?
PE Ratio	147.2x
Earnings	CN¥32.80m
Market Cap	CN¥4.83b

002094 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.5x
Enterprise Value/EBITDA	50.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 002094's PE Ratio compare to its peers?

The above table shows the PE ratio for 002094 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	31.5x
300740 SYoung Group	22.9x	23.7%	CN¥4.8b
603896 Zhejiang Shouxiangu Pharmaceutical	18.2x	19.4%	CN¥4.3b
301507 Hangzhou Minsheng Healthcare	51.4x	n/a	CN¥4.6b
001328 Dencare (Chongqing) Oral Care	33.5x	17.4%	CN¥5.1b
002094 Qingdao Kingking Applied Chemistry	147.2x	n/a	CN¥4.8b

Price-To-Earnings vs Peers: 002094 is expensive based on its Price-To-Earnings Ratio (147.2x) compared to the peer average (31.5x).

Price to Earnings Ratio vs Industry

How does 002094's PE Ratio compare vs other companies in the CN Personal Products Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002094 is expensive based on its Price-To-Earnings Ratio (147.2x) compared to the CN Personal Products industry average (35.1x).

Price to Earnings Ratio vs Fair Ratio

What is 002094's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002094 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	147.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 002094's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Byhealth

CN¥20.9b

Develops and sells dietary supplements.

300146

CN¥12.40

-3.9%

-32.3%

Shenzhen Breo Technology

CN¥2.5b

Researches and develops portable massage products for headache swelling, eye fatigue, and shoulder and neck pain.

688793

CN¥29.69

-1.7%

-24.3%

SYoung Group

CN¥4.8b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.30

-4.1%

-27.0%